全球首个糖尿病神经痛贴剂获批，填补外用药物治疗空白

Core Viewpoint - Beijing Tide Pharmaceutical Co., Ltd. has received approval for its self-developed lidocaine gel patch (Debain) to treat diabetic peripheral neuropathic pain, making it the first and only approved topical analgesic for this indication globally [1][2] Group 1: Product Approval and Market Potential - The Debain patch fills a significant treatment gap for diabetic peripheral neuropathic pain, which affects over 200 million diabetes patients in China, with a substantial portion likely to develop this condition [1] - Approximately two-thirds of type 2 diabetes patients may experience diabetic peripheral neuropathy, with over half of these patients progressing to diabetic peripheral neuropathic pain, characterized by severe pain that impacts sleep and emotional well-being [1] Group 2: Product Features and Efficacy - The Debain patch utilizes a unique hydrogel cross-linking technology, delivering 700mg of high-dose lidocaine, promoting effective drug penetration while minimizing skin adverse reactions, and providing sustained analgesic effects for up to 12 hours [2] - Long-term follow-up data indicate that the patch is suitable for prolonged use, with a pain relief rate of 78.2% when used in conjunction with oral medications, allowing some patients to reduce or discontinue oral medication [2]